Zisman D, Bitterman H, Shalom G, Feldhamer I, Comanesther D, Batat E, Greenberg-Dotan S, Cohen S, Cohen AD. Psoriatic arthritis treatment and the risk of herpes zoster. Ann Rheum Dis. 2016 Jan;75(1):131-5. Epub 2014 Sep 26. PMID: 25261573.

Ann Rheum Dis. 2016 Jan;75(1):131-5. doi: 10.1136/annrheumdis-2013-205148. Epub 2014 Sep 26.

Psoriatic arthritis treatment and the risk of herpes zoster.

Zisman D(1), Bitterman H(2), Shalom G(3), Feldhamer I(3), Comanesther D(3), Batat E(3), Greenberg-Dotan S(3), Cohen S(4), Cohen AD(5).

Author information:
(1)Department of Rheumatology, Carmel Medical Center, Haifa, Israel The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.
(2)The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel Chief Physician's Office Central Headquarters, Clalit Health Services, Tel Aviv, Israel.
(3)Chief Physician's Office Central Headquarters, Clalit Health Services, Tel Aviv, Israel.
(4)Department of Rheumatology, Carmel Medical Center, Haifa, Israel.
(5)Chief Physician's Office Central Headquarters, Clalit Health Services, Tel Aviv, Israel Faculty of Health Sciences, Siaal Research Center for Family Medicine and Primary Care, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

OBJECTIVES: To study the association between traditional disease-modifying antirheumatic drugs (c-DMARD) or anti-TNF-α agents and herpes zoster (HZ) in patients with psoriatic arthritis (PsA).

METHODS: A retrospective cohort study was conducted in patients with PsA between 2002 and 2013. Patients were grouped as follows: no DMARDs (Group A); c-DMARDs (Group B); anti-TNF-α agents (Group C); anti-TNF-α agents in combination with c-DMARDs (Group D). Crude incidence rates (IR) were calculated as number of HZ episodes per 1000 patient-years. A Cox regression model was used to adjust for HZ risk factors (age, gender, steroid use, Charlson Comorbidity Index score, and previous treatment) in order to estimate their contribution to the risk of the first HZ event.

RESULTS: The study included 3128 patients, mean age 50.26±14.54 years; 46.2% male. During a period of 20 096 person-years 182 HZ events were observed. The crude IR (95% CI) of HZ in the study population was 9.06 per 1000 patient-years, and in Groups A-D 7.36 (5.41 to 9.79), 9.21 (7.5 to 11.21), 8.64 (4.84 to 14.26), 17.86 (10.91 to 27.58), respectively. In a multivariate analysis, age (HR 1.01, 95% CI 1.00 to 1.02), treatment with steroids (HR 1.08, 95% CI 1.04 to 1.13), and a combination of anti-TNF-α agents and c-DMARDs (HR 2.37, 95% CI 1.32 to 4.22) were significantly associated with HZ events.

CONCLUSIONS: In our database, the risk of HZ was significantly increased with age, treatment with steroids, and combination of anti-TNF-α agents and c-DMARDs, but not with c-DMARDs or anti-TNF-α therapy alone. Time to HZ event was shorter in patients treated with anti -TNF-α agents.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

PMID: 25261573 [PubMed - indexed for MEDLINE]

האתר מעודכן נכון לתאריך:  22/05/2017 14:00:17
עבור לתוכן העמוד